Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +45.46% and +3.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?